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Background: Advanced inoperable hepatocellular carcinoma (HCC) conferring a grave 
prognosis may benefit from yttrium-90 (90Y) radioembolization.
Methods: Thirty patients with advanced inoperable HCC including those with any lesion .8 cm 
in maximal diameter or multiple bi-lobar lesions (totally more than five lesions), or portal 
vein thrombosis treated with radioembolization were reviewed. Treatment efficacy and safety 
were evaluated. Univariate and multivariate analyses were performed for identifying potential 
prognostic factors.
Results: After a median follow-up of 18.3 months, the response rate was 30.0%, and the 
disease control rate was 50.0%. Median overall progression-free survival (PFS) and overall 
survival (OS) were 3.3 months and 13.2 months, respectively. Longer median PFS was noted 
in those who had transarterial chemoembolization before radioembolization (7.3 months vs 
3.1 months; P=0.021) and duration of alfa-feto protein (AFP) response $6 months (11.8 months 
vs 3.0 months; P,0.001). Longer median OS was also revealed in those without portal vein 
thrombosis (17.1 months vs 4.4 months; P=0.015) and those whose duration of AFP response 
was $6 months (21.2 months vs 8.6 months; P=0.001). Seventeen patients (56.7%) developed 
treatment-related complications including five (16.7%) grade 3 events. Multivariate analysis 
revealed that treatment responders (P=0.001) and duration of AFP response $6 months 
(P=0.006) were prognostic of PFS, whereas the absence of portal vein invasion (P=0.025), 
treatment responders (P=0.010), and duration of AFP response $6 months (P=0.001) were 
prognostic of OS.
Conclusion: 90Y radioembolization is an alternative treatment with a promising outcome for 
poor-risk advanced inoperable HCC.
Keywords: radioembolization, transarterial chemoembolization, hepatocellular carcinoma, 
inoperable
Introduction
The overall prognosis of inoperable and unresectable hepatocellular carcinoma 
(HCC) is disappointing despite traditional and novel therapies including transarte-
rial chemoembolization (TACE), systemic chemotherapy, palliative external-beam 
radiotherapy, or sorafenib. Patients whose tumors demonstrated portal vein thrombosis 
(present in 15%–40% of all HCCs) belong to, in particular, a poor prognostic group, 
and they are relatively contraindicated to TACE.1–4 Radioembolization with yttrium-90 
(90Y) microspheres has been increasingly employed for unresectable HCCs which are 
not amenable to liver transplantation, resection, or local ablative therapies like radiofre-
quency ablation (RFA) and percutaneous ethanol injection.5–7 The microspheres labeled 
with 90Y lodged preferentially into the microvasculature of the tributaries of tumor-
feeding hepatic arteries, after careful and selective endovascular cannulation. They 
deliver high-energy (maximum 2.3 MeV) pure β-emitting fast electrons over a short 
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median depth of 2.4 mm, thus minimizing radiation hazard 
to surrounding normal liver parenchyma. Previous studies 
revealed an improved median survival of 7–41.6 months 
in patients with intermediate-to-advanced HCC following 
radioembolization which produced a response rate between 
20% and 77%.8,9 Radioembolization has also been found 
safe with promising results in those who had portal vein 
thrombosis.10–12 Besides, it was also found effective in 
patients who had hepatitis B infection and in Asian patients 
who had a high incidence of hepatitis B-associated HCC.13,14 
We reviewed the efficacy and safety of radioembolization in 
patients with advanced inoperable HCC, defined as either any 
inoperable lesion .8 cm in maximal diameter or multiple 
bi-lobar lesions (totally more than five lesions) or portal 
vein thrombosis.
Materials and methods
Patients
This study was approved by the local institutional review 
board of the University of Hong Kong/Hospital Author-
ity Hong Kong West Cluster, Hong Kong. This study was 
conducted in adherence with the guidelines of the Declara-
tion of Helsinki. Patients with advanced HCC treated with 
radioembolization were reviewed. They were all treated 
with radioembolization with 90Y resin microspheres (SIR-
spheres; SIRTEX Medical, Sydney, Australia) between 
January 2009 and December 2013 in Queen Mary Hospital, 
The University of Hong Kong, after a consensus was made 
in a multidisciplinary tumor board consisting of hepatobiliary 
surgeons, radiologists, and oncologists. Glass microspheres 
from TheraSphere® were not used as they have not yet been 
licensed in Hong Kong at the time of publication. After 
obtaining informed written consent from all of the partici-
pants, and reviewing baseline serum hematology, renal and 
liver biochemistry, alfa-feto protein (AFP) response, clotting 
profile, and image of the three-phase contrast-enhanced com-
puted tomography (CT) scan of the liver, upper abdomen, and 
thorax, the patients underwent a planned hepatic angiography 
by interventional radiologists with specialization in radi-
oembolization to delineate the course of hepatic arteries and 
identify any aberrant and collateral feeding vessels. Hyper-
selective cannulation of right or left hepatic artery followed 
by injection of technetium 99m macroaggregated albumin 
(99mTc-MAA) and also subsequent 90Y microspheres was 
performed for tumors situated mainly in a specific hepatic 
lobe after consensus by interventional radiologists, nuclear 
medicine physicians, medial physicists, and oncologists. 
Otherwise, both MAA and 90Y microspheres were injected 
through the hepatic artery proper. If necessary, prophylactic 
embolization of gastroduodenal, gastric, and/or other extrahe-
patic arteries was performed to prevent undesirable delivery 
of microspheres into these vessels. Nuclear medicine physi-
cians then injected 99mTc-MAA into the hepatic artery for 
the determination of 99mTc uptake by tumor and normal liver 
(so as to calculate the tumor–normal liver ratio) and percent-
age of lung shunting by single-photon emission CT/CT scan. 
Those who had tumor–normal liver ratio ,2.0 or percentage 
of lung shunting .20% were excluded from subsequent 
radioembolization to avoid suboptimal treatment outcomes 
and unfavorable toxicities. Prescription of activity of actual 
90Y microspheres was based on body surface area model 
as previously described.15 The final prescribed activity of 
90Y was determined by clinical oncologists and medical 
physicists, aiming at a radiation dose .200 Gy to the tumor 
and ,80 Gy to the normal liver. Injection of 90Y microspheres 
was performed by trained clinical oncologists 1–2 weeks after 
MAA injection. Postradioembolization Bremsstrahlung scan 
was done 4–6 hours after treatment to evaluate the uptake of 
90Y microspheres by the tumors. Patients were discharged the 
next day after overnight observation. Serial blood tests every 
month and CT scan of the liver, upper abdomen, and thorax 
were performed every 3 months after radioembolization for 
monitoring treatment efficacy and complications. Treatment 
response was determined by both European Association for 
the Study of Liver criteria and modified response evaluation 
criteria in solid tumors, as they were shown to better correlate 
with survival as compared with World Health Organization 
criteria.16–18
statistical analysis
Chi-square tests and Mann–Whitney U-tests were per-
formed for comparison of discrete and continuous vari-
ables. Progression-free survival (PFS) was defined from 
the date of radioembolization to the date of radiological 
sign of progression or death from any cause, while overall 
survival (OS) was calculated from the date of radioembo-
lization to the date of death from any cause. Duration of 
AFP response was calculated from the date of baseline 
AFP before radioembolization to the date when there 
were two consecutive elevations of AFP above nadir 
following radioembolization. Kaplan–Meier methods 
were used to calculate survivals. Log-rank tests and Cox 
proportional hazards model were used for comparison of 
survivals among subgroups. Univariate and multivariate 
analyses were performed for any prognostic factors of 
survival outcomes. Only covariates considered significant 
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at P-value ,0.1 in the univariable analysis were included 
in the multivariate model. Treatment-related toxicity 
was all graded with National Cancer Institute Common 
Terminology Criteria for Adverse Events version 4.0.19 
Statistical significance was defined as P,0.05. All statis-
tical analyses were carried out by Statistical Package for 
Social Sciences version 20.
Results
Patient characteristics
The characteristics of all patients are shown in Table 1.  They 
all suffered from Barcelona Clinic Liver Cancer (BCLC) 
staging system either stage B or C diseases.20–22 Majorities 
had chronic hepatitis B infection and received antiviral 
therapy for .4 years. Eighteen (60.0%) had received 
prior therapy including TACE (15 patients, 50.0%), 
RFA (four patients, 13.3%), percutaneous ethanol injection 
(one patient, 3.3%), high-intensity focused ultrasonog-
raphy (HIFU) ablation (two patients, 6.7%), and tumor 
resection (six patients, 20.0%) and systemic treatment 
(three patients, 10.0%). The median number of lesions 
was 8 (range 6–18). The median volume of tumors and 
normal liver was 258.9 cm3 (30.1–2,314.9 cm3) and 
1,124.2 cm3 (540.4–1,773.5 cm3), respectively. Portal vein 
thrombosis was noted in 12 patients (40.0%). The median 
prescribed dose was 1.4 GBq (range 0.9–2.3 GBq). Prior 
Table 1 Patient and tumor characteristics
Patient and tumor characteristics All (30 patients) Non-portal vein 
thrombosis 
(18 patients)
Portal vein 
thrombosis 
(12 patients)
P-value
Median age, years (range) 63 (36–84) 61 (36–75) 64 (45–84) 0.200
sex (M/F) 26/4 15/3 11/1 0.511
Body surface area, m2 (range) 1.74 (1.31–2.07) 1.74 (1.45–1.93) 1.75 (1.31–2.07) 0.518
hepatitis B carrier 21 (70.0%) 16 (88.9%) 5 (41.7%) 0.006
hepatitis c carrier 2 (6.7%) 0 (0%) 2 (16.7%) 0.073
cirrhosis 16 (53.3%)  8 (44.4%) 8 (66.7%) 0.232
child–Pugh status 0.709
a 24 (80.0%) 14 (77.8%) 10 (83.3%)
B 6 (20.0%) 4 (22.2%) 2 (16.7%)
Bclc stage
B 18 (60.0%) 18 (100%) 0 (0%) ,0.001
c 12 (40.0%) 0 (0%) 12 (100%)
Median number of lesions (range) 8 (6–18) 7 (6–18) 8 (6–15) 0.582
Portal vein thrombosis 12 (40.0%) n/a 12 (100%) n/a
Main 8 (26.7%) n/a 8 (66.7%)
left only 1 (3.3%) n/a 1 (8.3%)
right only 3 (10.0%) n/a 3 (25.0%)
Prior Tace 15 (50.0%) 11 (61.1%) 4 (33.3%) 0.136
Prior rFa 4 (13.3%) 2 (11.1%) 2 (16.7%) 0.661
Prior Pei 1 (3.3%) 0 (0%) 1 (8.3%) 0.213
Prior hiFU ablation 2 (6.7%) 2 (11.1%) 0 (0%) 0.232
Prior tumor resection 6 (20.0%) 5 (27.8%) 1 (8.3%) 0.192
Prior systemic therapy 3 (10.0%) 2 (11.1%) 1 (8.3%) 0.804
Median aFP at baseline (ng/ml) (range) 31 (12–17,610) 406 (12–10,389) 221 (18–17,160) 0.232
Median volume of tumor (cm3) (range) 258.9 (30.1–2,314.9) 254.1 (36.2–2,314.9) 307.2 (30.1–894.5) 0.755
Median volume of normal liver (cm3) (range) 1,124.2 (540.4–1,773.5) 1,080.6 (631.0–1,644.9) 1,210.0 (540.4–1,773.5) 0.346
Median tumor/normal liver ratio (range) 3.9 (2.1–13.5) 3.9 (2.1–11.0) 4.1 (2.2–13.5) 0.982
Median lung shunting (%) (range) 6.7 (3.2–17.3) 6.9 (4.1–17.3) 6.7 (3.2–11.0) 0.325
artery embolization before radioembolization 4 (13.3%) 4 (22.2%) 0 (0%) 0.079
Median prescribed dose (gBq) (range) 1.4 (0.9–2.3) 1.5 (0.9–1.7) 1.39 (0.9–2.3) 0.755
Median dose to tumor (range) (gy) 233.0 (159.0–692.0) 230.0 (163.0–528.0) 241.0 (159.0–692.0) 0.517
Median dose to liver (range) (gy) 61.0 (34.0–83.0) 59.5 (44.0–83.0) 66.0 (34.0–80.0) 0.912
artery into which microspheres were injected 0.519
hepatic artery proper 7 (23.3%) 3 (16.7%) 4 (33.3%)
right hepatic artery 19 (63.4%) 12 (66.6%) 7 (58.4%)
left hepatic artery 4 (13.3%) 3 (16.7%) 1 (8.3%)
Abbreviations: aFP, alfa-feto protein; Bclc, Barcelona clinic liver cancer; hiFU, high-intensity focused ultrasonography; n/a, not applicable; Pei, percutaneous ethanol 
injection; rFa, radiofrequency ablation; Tace, transarterial chemoembolization.
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embolization of gastroduodenal artery was necessary in 
four patients (13.3%) before injection of 90Y microspheres 
to minimize radiation-induced gastroduodenitis and its 
complications.
Nine patients (30.0%) had local response including 
one patient with complete response lasting for 8 months, 
and an additional six patients (20.0%) had stable disease, 
resulting in a disease control rate of 50.0%. Response rate 
was lower in patients with portal vein thrombosis (16.7%) 
compared with those without thrombosis (38.9%), but this 
was statistically insignificant (P=0.193). The median PFS 
was 3.3 months, and the median OS was 13.2 months. 
Subgroup analysis revealed that those who received prior 
TACE before radioembolization enjoyed longer PFS 
(7.3 months) than those who did not (3.1 months; P=0.021) 
(Figure 1). In addition, those who had duration of AFP 
response $6 months after radioembolization exhibited 
longer PFS (11.8 months) than those whose AFP response 
was ,6 months after radioembolization (3.0 months; 
P,0.001) (Figure 1). Treatment responders (including 
complete and partial response) were also found to have 
longer PFS (11.8 months vs 3.1 months; P,0.001). Those 
without portal vein thrombosis had borderline longer PFS 
(4.5 months) than those whose tumor exhibited portal 
vein thrombosis (3.0 months; P=0.072). Upon progres-
sion to radioembolization, 15 patients (50.0%) received 
further treatment including TACE (eight patients, 26.7%), 
RFA (four patients, 13.3%), HIFU (one patient, 3.3%), 
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Figure 1 Progression-free survival of patients (A) with or without prior Tace before radioembolization, and (B) those who had duration of aFP response $6 months or 
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Abbreviations: aFP, alfa-feto protein; Tace, transarterial chemoembolization.
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metastasectomy (two patients, 6.7%), and other locoregional 
therapy (two patients, 6.7%) and systemic therapy with 
sorafenib and chemotherapy (seven patients, 23.3%). 
Longer median OS was seen in those without portal vein 
thrombosis (17.1 months vs 4.4 months; P=0.015) and 
those whose AFP duration was $6 months after radi-
oembolization (21.2 months vs 8.6 months; P=0.001) 
compared to their counterparts (Figure 2). More impor-
tantly, treatment responders definitely derived longer 
median OS (21.2 months vs 8.6 months; P=0.015) than 
nonresponders.
Univariate and multivariate analysis
Univariate and multivariate analyses were performed 
for predictors of PFS and OS (Table 2). Univariate 
analysis revealed that prior TACE (P=0.046), tumor 
volume (P=0.045), treatment responders (P=0.003), 
and duration of AFP response $6 months (P=0.001) 
were prognostic of PFS, while portal vein thrombosis 
(P=0.020), treatment responders (P=0.024), and duration 
of AFP response $6 months (P=0.005) were prognostic 
factors of OS. In multivariate analysis, treatment respond-
ers (P=0.001) and duration of AFP response $6 months 
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Figure 2 Overall survival of patients (A) with or without portal vein thrombosis, and (B) those who had duration of aFP response $6 months or ,6 months and (C) 
treatment response after radioembolization.
Abbreviation: aFP, alfa-feto protein.
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(P=0.006) were prognostic of PFS, whereas portal vein 
thrombosis (P=0.025), treatment responders (P=0.010), 
and duration of AFP response $6 months (P=0.001) were 
prognostic of OS.
Safety profiles
Complications developed in 17 patients (56.7%), among 
which grade 3 events were noted in five patients (16.7%) 
after radioembolization as shown in Table 3. Four patients 
(13.3%) developed gastric and duodenal ulcers, and micro-
spheres were identified under microscopy in gastric and 
duodenal biopsies. Three patients had their ulcers improved 
after use of proton pump inhibitors and symptomatic care 
except one who eventually received gastrectomy despite 
prior prophylactic embolization of gastroduodenal artery 
before radioembolization. Another patient developed self-
limiting cholecystitis which was most probably attributed to 
incidental spilling of microspheres into his cystic artery. All 
grade 3 or above gastrointestinal complications developed 
in the first eight patients at the time when all interventional 
radiologists and oncologists were still gaining experience, 
and there were no such complications afterward. No 
grade $4 complications or treatment-related mortality 
occurred.
Discussion
HCC is a common cancer worldwide which claims 700,000 
lives every year.23 The incidence is highest in Asian and 
African countries secondary to the high incidence of chronic 
hepatitis B infection. TACE has been the standard treat-
ment for unresectable HCC for more than two decades.24–26 
However, it is relatively contraindicated in those whose 
tumor harbored portal vein thrombosis, which is present in 
10%–40% of patients at the time of diagnosis.3,27,28 TACE is 
associated with an increased risk of ischemia and necrosis of 
the remaining normal liver parenchyma and treatment-related 
mortality in those having portal vein thrombosis in their 
tumors.29 Thus, only very limited treatment options including 
systemic therapy and best supportive care were available. 
Radioembolization with 90Y microspheres is increasingly 
gaining popularity as first-line treatment or subsequent 
therapy after failure to prior locoregional therapy for unre-
sectable HCC. Accumulating evidence has proven its efficacy 
and prolongation of survival in patients with intermediate-
to-advanced HCC. Tumor cell death is mainly contributed 
by local short-distance irradiation by 90Y microspheres rather 
than embolization. In fact, an oxygenated microenvironment 
with free radical generation enhances more radiation-induced 
tumor cell death.30 Treatment responders definitely enjoyed a 
longer PFS and OS in our study, essentially comparable with 
the long-term results of a previously reported prospective 
Table 2 association of clinicopathological parameters with survival outcomes in univariate and multivariate analyses
Parameter Univariate analysis Multivariate analysis
PFS OS PFS OS
Hazard ratio 
(95% CI)
P-value Hazard ratio 
(95% CI)
P-value Hazard ratio 
(95% CI)
P-value Hazard ratio 
(95% CI)
P-value
Prior Tace 0.404 
(0.166–0.984)
0.046 0.407 
(0.160–1.038)
0.060 0.543 
(0.211–1.202)
0.122 0.480 
(0.205–1.247)
0.135
Portal vein 
thrombosis
0.444 
(0.178–1.111)
0.083 0.322 
(0.124–0.836)
0.020 0.567 
(0.208–1.221)
0.131 0.310 
(0.112–0.859)
0.025
Tumor volume 2.200 
(1.018–4.756)
0.045 1.407 
(0.650–3.043)
0.386 2.187 
(0.879–4.801)
0.129 nD nD
Treatment 
responders
0.043 
(0.005–0.350)
0.003 0.235 
(0.067–0.827)
0.024 0.079 
(0.010–0.636)
0.001 0.235 
(0.067–0.827)
0.010
Duration of aFP 
response $6 months
0.124 
(0.036–0.433)
0.001 0.111 
(0.023–0.523)
0.005 0.205 
(0.056–0.749)
0.006 0.104 
(0.021–0.513)
0.001
Note: Only variables found significant in univariate analysis (P,0.1) were considered in multivariate analysis.
Abbreviations: AFP, alfa-feto protein; CI, confidence interval; ND, not done; OS, overall survival; PFS, progression-free survival; TACE, transarterial chemoembolization.
Table 3 radioembolization-related toxicities
Toxicities All grades (%) Grade 3 events (%)
nausea 4 (13.3) 1 (3.3)
Vomiting 5 (16.7) 1 (3.3)
anorexia 6 (20.0) 0 (0)
Malaise 2 (6.7) 1 (3.3)
Fever 4 (13.3) 2 (6.7)
abdominal pain 8 (26.7) 0 (0)
anemia 1 (3.3) 1 (3.3)
anorexia 5 (20.0) 0 (0)
Peptic/duodenal ulcers 4 (13.3) 2 (6.7)
cholecystitis 1 (3.3) 0 (0)
impaired liver function 3 (10.0) 0 (0)
Note: grading of toxicities was based on common Terminology criteria for 
adverse events version 4.0.
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90Y radioembolization for advanced inoperable hcc
single-center study by Salem et al.9 On top of that, we were 
able to show that AFP response $6 months after radioem-
bolization was translated into a lengthened PFS and OS. 
Our current study also echoed with other previous studies 
that radioembolization could bring some benefits and effi-
cacy to those who had portal vein thrombosis in their HCC, 
albeit a shorter PFS and OS as compared to those without 
portal vein thrombosis. Our results agreed with those in 
previous studies that portal vein thrombosis is an unfa-
vorable prognostic group even after radioembolization.30 
Salem et al reported median survival of 7.7 months and 
4.5 months, respectively, after radioembolization in patients 
with Child–Pugh Class A and B status and main portal vein 
thrombosis.9 A median survival between 3.2 months and 
10 months was observed in those with portal vein thrombosis 
as compared to 15.3–16.4 months in those without portal vein 
thrombosis in another four studies.12,31,32 Patients who had 
branched first-order portal vein thrombosis survived longer 
(6.5–16.6 months) than those who had main portal vein 
thrombosis (4.4–7.5 months).33,34 More recently, Kokabi et al 
demonstrated that Eastern Cooperative Oncology Group 
performance status of 0, Child–Pugh Class A, and lung shunt-
ing fraction ,10% were independent prognostic factors of 
time to progression after radioembolization in patients who 
had portal vein thrombosis in their HCC.35
Since treatment for patients with portal vein thrombosis 
is essentially palliative, it is crucial to offer them effective 
treatment with minimal toxicity. Targeted therapy with 
sorafenib is another treatment option, but there was only a 
modest improvement in survival.36,37 Recently, Hong Kong 
has devised and published a new Hong Kong Liver Cancer 
Staging System with treatment stratification for patients 
with HCC.38 It was proven more superior to BCLC system 
in prognosticating the survival outcomes of patients with 
HCC. However, it did not include patients treated with 
external radiotherapy or radioembolization as the cohort 
included those diagnosed between 1995 and 2008. The 
patients in our current study belonged to those classified as 
between stage IIIb and IVb diseases under this new Hong 
Kong staging system and enjoyed a longer survival than 
their counterparts in this large cohort (median OS between 
2.13 months and 6.01 months). With the incorporation of 
radioembolization as part of the management protocol for 
these poor-risk groups, their survival would definitely be 
further improved.
Toxicity profiles in our study were also comparable 
to other reported studies.39,40 One patient developed grade 
3 peptic ulcer despite prior embolization of gastroduodenal 
artery and eventually gastrectomy was carried out for 
persistent bleeding ulcer and anemia. Radiation-related 
peptic and duodenal ulcers were well recognized side effects 
in ~10% of patients due to the inadvertent delivery of micro-
spheres to the gastroduodenal artery and less commonly short 
gastric arteries. It is sometimes quite long lasting and trouble-
some to patients, which is refractory to supportive treatment 
and proton pump inhibitors. Learning from experience may 
also be important as we encountered no more patients who 
suffered from this gastrointestinal complication after radi-
oembolization from the ninth patient onward. Meticulous 
and slow injection of microspheres may reduce the chance 
of backflow to the gastroduodenal artery and other small 
arteries supplying the stomach and duodenum. Prophylactic 
embolization and prophylactic use of proton pump inhibitors 
may also be helpful.
As a conclusion, our study demonstrated the feasibility 
and efficacy of radioembolization in patients with advanced 
inoperable HCC with a modest improvement in survival. 
It may provide an alternative treatment option for this poor 
prognostic group.
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